Vybion

Vybion has pioneered vectorized Intrabodies, the delivery of functional antibody fragments in the scFv format to cells using Adeno associated virus (AAV). The Company has Orphan Drug Designation from the FDA for INT41 to treat Huntington’s disease a progressively fatal protein aggregating condition leading to loss of neurons. A recent preIND meeting has established IND enabling work to be completed before submitting and IND to start human clinical trials.